Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00379587 | Rituximab for Prevention of Chronic GVHD | completed | Phase 1 / Phase 2 | 65 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00724009 | Clofarabine Bone Marrow Cytoreduction | completed | Phase 2 | 29 | University of ChicagoOTHER | 1 | Mar 18, 2014 | clinicaltrials |
| NCT00322387 |
| Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients |
| completed |
| Phase 2 |
| 40 |
| Genzyme, a Sanofi CompanyINDUSTRY |
| 1 |
| Mar 13, 2014 |
| clinicaltrials |
| NCT00322491 | Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients | completed | Phase 2 | 49 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00322842 | Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients | completed | Phase 2 | 35 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00328198 | Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia | completed | Phase 2 | 86 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Mar 13, 2014 | clinicaltrials |
| NCT00396201 | AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease | completed | Phase 2 | 22 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00444912 | The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD) | completed | Phase 2 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00514579 | Adult Double Cord Blood Transplant Study | completed | Phase 2 | 56 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Mar 10, 2014 | clinicaltrials |
| NCT01340651 | Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients | completed | Phase 2 | 41 | Incyte CorporationINDUSTRY | 1 | Mar 10, 2014 | clinicaltrials |
| NCT00004145 | Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 2 | 16 | University of ChicagoOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00396266 | AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF | completed | Phase 2 | 22 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00943592 | Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies | completed | Phase 1 / Phase 2 | 82 | University of ChicagoOTHER | 1 | Feb 27, 2014 | clinicaltrials |
| NCT00004010 | Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease | completed | Phase 2 | 99 | Children's Oncology GroupNETWORK | 3 | Feb 26, 2014 | clinicaltrials |
| NCT00039416 | Imatinib Mesylate in Treating Patients With Myelofibrosis | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2014 | clinicaltrials |
| NCT00970021 | Agaricus Blazei Murill in Patients With Multiple Myeloma | completed | Phase 2 | 39 | Ullevaal University HospitalOTHER | 1 | Feb 25, 2014 | clinicaltrials |
| NCT00006462 | Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia | completed | Phase 2 | 32 | Children's Oncology GroupNETWORK | 7 | Feb 20, 2014 | clinicaltrials |
| NCT00022126 | Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia | completed | Phase 2 | 6 | Children's Oncology GroupNETWORK | 3 | Feb 20, 2014 | clinicaltrials |
| NCT00070174 | Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy | completed | Phase 2 | 350 | Children's Oncology GroupNETWORK | 5 | Feb 20, 2014 | clinicaltrials |
| NCT00002756 | Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 2 | 221 | Children's Oncology GroupNETWORK | 4 | Feb 14, 2014 | clinicaltrials |
| NCT00098683 | Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes | completed | Phase 2 | 10 | Children's Oncology GroupNETWORK | 4 | Feb 13, 2014 | clinicaltrials |
| NCT00665314 | Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). | completed | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Feb 11, 2014 | clinicaltrials |
| NCT00774046 | High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML | completed | Phase 2 | 32 | University of ChicagoOTHER | 1 | Feb 11, 2014 | clinicaltrials |
| NCT00930098 | A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic Leukaemia | completed | Phase 2 | 74 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Feb 11, 2014 | clinicaltrials |
| NCT00410163 | Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients(BIFROST) | completed | Phase 2 | 61 | GlaxoSmithKlineINDUSTRY | 2 | Feb 10, 2014 | clinicaltrials |
| NCT00376467 | STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia | completed | Phase 2 | 105 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 7, 2014 | clinicaltrials |
| NCT00066248 | Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment | completed | Phase 2 | 70 | University of South FloridaOTHER | 3 | Feb 3, 2014 | clinicaltrials |
| NCT00006052 | STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia | completed | Phase 2 | — | NovartisINDUSTRY | 1 | Jan 31, 2014 | clinicaltrials |
| NCT00394836 | HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab | completed | Phase 2 | 116 | GlaxoSmithKlineINDUSTRY | 1 | Jan 29, 2014 | clinicaltrials |
| NCT00070447 | Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 5 | Jan 28, 2014 | clinicaltrials |
| NCT00727831 | Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | completed | Phase 1 / Phase 2 | 4 | University College, LondonOTHER | 1 | Jan 27, 2014 | clinicaltrials |
| NCT00750815 | Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 58 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 20, 2014 | clinicaltrials |
| NCT00617591 | Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) | completed | Phase 2 | 57 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 17, 2014 | clinicaltrials |
| NCT01037478 | Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma(SAPHIRE) | completed | Phase 2 | 37 | 4SC AGINDUSTRY | 3 | Jan 16, 2014 | clinicaltrials |
| NCT00439231 | Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 33 | Georg Aue, M.D.NIH | 1 | Jan 13, 2014 | clinicaltrials |
| NCT00003305 | Aminopterin in Treating Patients With Refractory Leukemia | completed | Phase 2 | 75 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00017589 | Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia | completed | Phase 2 | — | Genta IncorporatedINDUSTRY | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00894049 | A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation(ITAC02-01) | completed | Phase 2 | 148 | Institut Paoli-CalmettesOTHER | 1 | Jan 1, 2014 | clinicaltrials |
| NCT00656812 | Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma | completed | Phase 2 | 40 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Dec 24, 2013 | clinicaltrials |
| NCT00040690 | Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia | completed | Phase 2 | 120 | Medical Research CouncilOTHER_GOV | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00071955 | Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma | completed | Phase 2 | — | Genitope CorporationINDUSTRY | 2 | Dec 19, 2013 | clinicaltrials |
| NCT00053092 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma | completed | Phase 2 | 82 | Institute of Cancer Research, United KingdomOTHER | 2 | Dec 18, 2013 | clinicaltrials |
| NCT00055718 | Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy | completed | Phase 2 | 50 | Herbert Irving Comprehensive Cancer CenterOTHER | 2 | Dec 18, 2013 | clinicaltrials |
| NCT00185445 | Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL | completed | Phase 2 | 62 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00311129 | Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL | completed | Phase 2 | 41 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00688883 | Fludara (Oral) Phase II Study for Indolent Lymphoma | completed | Phase 2 | 52 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00165282 | Mindfulness Meditation in Bone Marrow Transplantation | completed | Phase 2 / Phase 3 | 241 | Emory UniversityOTHER | 1 | Nov 28, 2013 | clinicaltrials |
| NCT00373906 | Velcade in MALT Lymphoma Patients | completed | Phase 2 | 16 | Medical University of ViennaOTHER | 0 | Nov 27, 2013 | clinicaltrials |
| NCT00472849 | Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias | completed | Phase 1 / Phase 2 | 92 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 26, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Mar 19, 2014source: clinicaltrials